Zobrazeno 1 - 10
of 7 280
pro vyhledávání: '"direct‐acting antivirals"'
Autor:
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Hsing-Hung Cheng, Mao-Wang Ho, Chih-Yu Chi, Jung-Ta Kao
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 57, Iss 6, Pp 840-853 (2024)
Background/Purpose: There are limited studies performing paired liver biopsies in chronic hepatitis C (CHC) patients treated with direct-acting antivirals (DAA). We aimed to investigate the predictors of liver fibrosis changes assessed by paired live
Externí odkaz:
https://doaj.org/article/124843e934d749ca8c837a4fd48f2d3e
Autor:
Fernando Chacón, Luis Morano, Jordi Navarro, Rafael Granados, Josep Mª Llibre, Pablo Ryan, Teresa Aldámiz-Echevarria, Luz Martín Carbonero, Marc Puigvehí, Imma Clotet-Codina, Nuria Sanchez-Vega, Enrique Vacas, Oscar Rincón, Juan Berenguer, Javier Crespo, Carlos Roncero
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Hepatitis C virus (HCV) reinfection following successful treatment threatens the achievement of HCV elimination. The primary aim of this study is to assess reinfection rate three years after sustained virologic response (SVR) in p
Externí odkaz:
https://doaj.org/article/8b8343c884894a8090d0c57af0718ffc
Autor:
Dorota Zarębska-Michaluk, Michał Brzdęk, Olga Tronina, Justyna Janocha-Litwin, Marek Sitko, Anna Piekarska, Jakub Klapaczyński, Anna Parfieniuk-Kowerda, Barbara Sobala-Szczygieł, Magdalena Tudrujek-Zdunek, Łukasz Laurans, Robert Flisiak
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Eliminating hepatitis C virus (HCV) infections is a goal set by the World Health Organization. This has become possible with the introduction of highly effective and safe direct-acting antivirals (DAA) but limitations remain due t
Externí odkaz:
https://doaj.org/article/2b3b1b2c568045c6bb363b56381eaabf
Autor:
Anna S. F. Lok
Publikováno v:
Gut and Liver, Vol 18, Iss 4, Pp 593-601 (2024)
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocell
Externí odkaz:
https://doaj.org/article/cf9f566970f640ac8ddce25d7e3a5556
Publikováno v:
Journal of Biological Dynamics, Vol 18, Iss 1 (2024)
In a recent study, a mathematically identical ODE model is derived from a multiscale PDE model of hepatitis C virus infection, which helps to overcome the limitations of the PDE model in the analysis. Here, an extended proposed model is formulated fo
Externí odkaz:
https://doaj.org/article/7c8e04621bcc4914b976db093c6d06eb
Autor:
Lucy X. Li, Jessica S. Lin, Sean Tackett, Amanda Bertram, Stephen D. Sisson, Darius Rastegar, Megan E. Buresh
Publikováno v:
American Journal of Medicine Open, Vol 12, Iss , Pp 100077- (2024)
Background: The introduction of direct-acting antivirals (DAA) has revolutionized hepatitis C virus (HCV) treatment but has not translated into an appreciable decline in HCV prevalence, which is estimated to be 2.4 million in the United States. Effor
Externí odkaz:
https://doaj.org/article/4e03ce20aac24e4794f414fb49fd0543
Publikováno v:
Global Public Health, Vol 19, Iss 1 (2024)
The local manufacture of advanced pharmaceutical products has been a long-standing objective of health and industry policy in many developing countries, including in Latin America. This strategy has been applied to fight epidemics such as HIV/AIDS, m
Externí odkaz:
https://doaj.org/article/8988610a47794394b5810e62e4f74f68
Autor:
Ivan Gentile, Giancarlo Agnelli, Angelo Avogaro, Claudio Borghi, Alessia Ciancio, Ernesto Claar, Patrizio Pasqualetti, Pasquale Perrone Filardi
Publikováno v:
Italian Journal of Medicine, Vol 18, Iss 4 (2024)
To date, no retrospective or real-world studies have comprehensively examined the interactions between direct-acting antivirals (DAAs) and widely used medications such as novel oral anticoagulant, statins, and antihypertensive agents. However, clinic
Externí odkaz:
https://doaj.org/article/79ef50596dd640da94e5784e129c6c60
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract Direct‐acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment through their high cure rates and improved safety profiles. We aimed to evaluate the efficacy and safety, and identify the optimal combination, of DAAs f
Externí odkaz:
https://doaj.org/article/521401171f9b4d81a31f26e95dc28785
Publikováno v:
Hepatic Medicine: Evidence and Research, Vol Volume 16, Pp 37-44 (2024)
Izere Salomon,1,2 Sibomana Olivier,1 Ndayambaje Egide1 1Department of General Medicine and Surgery, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda; 2YP-CDN Rwanda (Rwanda Young Professional Chronic Disease Network), Kig
Externí odkaz:
https://doaj.org/article/9f1eeaef64ff49cca263771c5c99eb16